Focused On-demand Library for Galectin-10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q05315

UPID:

LEG10_HUMAN

Alternative names:

Charcot-Leyden crystal protein; Eosinophil lysophospholipase; Lysolecithin acylhydrolase

Alternative UPACC:

Q05315; C5HZ13; C5HZ14; Q0VDE3

Background:

Galectin-10, also known as Charcot-Leyden crystal protein, Eosinophil lysophospholipase, and Lysolecithin acylhydrolase, plays a pivotal role in immune regulation. It is recognized for its ability to regulate immune responses through the identification of cell-surface glycans. This protein is crucial for the anergy and suppressive function of CD25-positive regulatory T-cells (Treg), which are essential components of the immune system.

Therapeutic significance:

Understanding the role of Galectin-10 could open doors to potential therapeutic strategies. Its involvement in the regulation of immune responses highlights its potential as a target for therapeutic intervention in diseases where the immune system plays a critical role.